Abeona Therapeutics IncNASDAQ:ABEO
- LAST PRICE6.3900
- TODAY'S CHANGE (%)-0.0200 (-0.3120%)
- Bid / Lots6.3000/ 1
- Ask / Lots6.4800/ 5
- Open / Previous Close6.4600 / 6.4100
- Day Range
- 52 Week Range
- Volume165,077
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABEO |
|---|---|---|
| 09:32 ET | 9688 | 6.41 |
| 09:33 ET | 700 | 6.3 |
| 09:35 ET | 1100 | 6.41 |
| 09:37 ET | 500 | 6.41 |
| 09:42 ET | 3159 | 6.3 |
| 09:46 ET | 155 | 6.3831 |
| 09:48 ET | 400 | 6.35 |
| 09:50 ET | 290 | 6.37 |
| 09:51 ET | 100 | 6.35 |
| 09:55 ET | 1884 | 6.3 |
| 10:00 ET | 800 | 6.3 |
| 10:02 ET | 1530 | 6.3 |
| 10:04 ET | 582 | 6.315 |
| 10:06 ET | 2377 | 6.3277 |
| 10:08 ET | 300 | 6.32 |
| 10:09 ET | 200 | 6.33 |
| 10:11 ET | 1527 | 6.33 |
| 10:13 ET | 1995 | 6.33 |
| 10:15 ET | 1100 | 6.35 |
| 10:20 ET | 100 | 6.38 |
| 10:24 ET | 4103 | 6.34 |
| 10:26 ET | 6442 | 6.31 |
| 10:33 ET | 1722 | 6.31 |
| 10:36 ET | 6604 | 6.275 |
| 10:40 ET | 2026 | 6.2641 |
| 10:47 ET | 100 | 6.275 |
| 10:49 ET | 100 | 6.29 |
| 10:51 ET | 700 | 6.295 |
| 10:54 ET | 200 | 6.292 |
| 10:56 ET | 220 | 6.33 |
| 11:00 ET | 100 | 6.34 |
| 11:02 ET | 200 | 6.34 |
| 11:03 ET | 2048 | 6.33 |
| 11:07 ET | 100 | 6.33 |
| 11:09 ET | 1300 | 6.34 |
| 11:14 ET | 1094 | 6.32 |
| 11:16 ET | 492 | 6.33 |
| 11:18 ET | 9900 | 6.25 |
| 11:20 ET | 418 | 6.26 |
| 11:23 ET | 100 | 6.2683 |
| 11:25 ET | 200 | 6.2688 |
| 11:30 ET | 200 | 6.26 |
| 11:32 ET | 4522 | 6.195 |
| 11:34 ET | 188 | 6.195 |
| 11:36 ET | 1950 | 6.2 |
| 11:38 ET | 2400 | 6.2 |
| 11:41 ET | 1199 | 6.215 |
| 11:43 ET | 5100 | 6.21 |
| 11:45 ET | 399 | 6.2 |
| 11:52 ET | 140 | 6.21 |
| 11:56 ET | 200 | 6.21 |
| 11:57 ET | 100 | 6.2 |
| 11:59 ET | 1050 | 6.185 |
| 12:03 ET | 700 | 6.21 |
| 12:08 ET | 200 | 6.225 |
| 12:10 ET | 500 | 6.2399 |
| 12:12 ET | 320 | 6.24 |
| 12:14 ET | 3580 | 6.24 |
| 12:15 ET | 500 | 6.25 |
| 12:17 ET | 200 | 6.25 |
| 12:19 ET | 300 | 6.25 |
| 12:21 ET | 500 | 6.26 |
| 12:24 ET | 8978 | 6.29 |
| 12:26 ET | 400 | 6.32 |
| 12:28 ET | 100 | 6.33 |
| 12:30 ET | 1730 | 6.36 |
| 12:32 ET | 1057 | 6.35 |
| 12:33 ET | 100 | 6.36 |
| 12:35 ET | 4677 | 6.4 |
| 12:37 ET | 3318 | 6.375 |
| 12:46 ET | 2040 | 6.4 |
| 12:48 ET | 1022 | 6.4 |
| 12:50 ET | 100 | 6.4 |
| 12:51 ET | 3109 | 6.4 |
| 12:53 ET | 962 | 6.3996 |
| 12:57 ET | 840 | 6.39 |
| 01:00 ET | 7267 | 6.39 |
Nov 27, 2024
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025, from 7:01AM ET on Wednesday Nov 27, 2024 by Dow Jones
7:01AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 25, 2024
DJ Abeona Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 7:56AM ET on Monday Nov 25, 2024 by Dow Jones
7:56AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 14, 2024
Abeona Therapeutics(R) Reports Third Quarter 2024 Financial Results and Recent Corporate Updates, from 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
7:30AM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Abeona Therapeutics 3Q Loss/Shr 63c >ABEO, from 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Abeona Therapeutics Inc | 278.6M | -2.8x | --- |
Perspective Therapeutics Inc | 277.8M | -3.5x | --- |
Ocugen Inc | 282.5M | -5.3x | --- |
Atea Pharmaceuticals Inc | 278.7M | -1.7x | --- |
Nautilus Biotechnology Inc | 281.3M | -4.0x | --- |
aTyr Pharma Inc | 288.8M | -3.8x | --- |
Company Information
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Contact Information
- Headquarters
- 6555 CARNEGIE AVE, 4TH FLOORCLEVELAND, OH, United States 44103
- Phone
- 646-813-4701
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Chief Operating Officer, Director
- Michael Amoroso
- President, Chief Executive Officer, Director
- Vishwas Seshadri
- Chief Financial Officer
- Joseph Vazzano
- General Counsel
- Brendan O Malley
- Independent Director
- Leila Alland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $278.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-2.29 |
Book Value | $0.56 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
